Publications by authors named "David Eberhard"

Claim this Profile
N
Neurodevelopmental disorders and comorbidity in young adults attending a psychiatric outpatient clinic.
David Eberhard, Eva Billstedt, Christopher Gillberg

Psychiatry Res· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Data-driven analysis of gaze patterns in face perception: Methodological and clinical contributions.
Paolo Masulli, Martyna Galazka, David Eberhard, Jakob Åsberg Johnels, Christopher Gillberg

Cortex· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Tumor Purity Metrics in Next-generation Sequencing for Clinical Practice: The Integrated Interpretation of Neoplastic Cellularity and Sequencing Results (IINCaSe) Approach.
Nirali M Patel, Heejoon Jo, David A Eberhard, Xiaoying Yin, Michele C Hayward

Appl Immunohistochem Mol Morphol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimum Technical Data Elements for Liquid Biopsy Data Submitted to Public Databases.
Phillip G Febbo, Anne-Marie Martin, Howard I Scher, J Carl Barrett, Julia A Beaver, David A Eberhard

Clin Pharmacol Ther· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing Next-Generation Sequencing-Guided Cancer Care Through Cognitive Computing.
Nirali M Patel, Vanessa V Michelini, Jeff M Snell, Saianand Balu, Alan P Hoyle, David A Eberhard

Oncologist· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic accuracy and prediction increment of markers of epithelial-mesenchymal transition to assess cancer cell detachment from primary tumors.
Evan L Busch, Prabhani Kuruppumullage Don, Haitao Chu, David B Richardson, Temitope O Keku, David A Eberhard

BMC Cancer· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Myron S Czuczman, Marek Trněný, Andrew Davies, Simon Rule, Kim M Linton, David A Eberhard

Clin Cancer Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The molecular basis of breast cancer pathological phenotypes.
Yujing J Heng, Susan C Lester, Gary Mk Tse, Rachel E Factor, Kimberly H Allison, David A Eberhard

J Pathol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Human Papillomavirus Infection in Cancer Tissue by Targeted Next-generation Sequencing.
Nathan D Montgomery, Joel S Parker, David A Eberhard, Nirali M Patel, Karen E Weck

Appl Immunohistochem Mol Morphol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC.
Xiaobei Zhao, Anyou Wang, Vonn Walter, Nirali M Patel, David A Eberhard

PLoS One· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating markers of epithelial-mesenchymal transition to identify cancer patients at risk for metastatic disease.
Evan L Busch, Temitope O Keku, David B Richardson, Stephanie M Cohen, David A Eberhard

Clin Exp Metastasis· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma.
William R Jeck, Joel Parker, Craig C Carson, Janiel M Shields, Maria J Sambade, David A Eberhard

Pigment Cell Melanoma Res· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Criteria for the use of omics-based predictors in clinical trials.
Lisa M McShane, Margaret M Cavenagh, Tracy G Lively, David A Eberhard, William L Bigbee

Nature· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration.
Lisa M McShane, Margaret M Cavenagh, Tracy G Lively, David A Eberhard, William L Bigbee

BMC Med· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tissue pattern recognition error rates and tumor heterogeneity in gastric cancer.
Steven J Potts, Sarah E Huff, Holger Lange, Vladislav Zakharov, David A Eberhard

Appl Immunohistochem Mol Morphol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue.
Steven J Potts, Joseph S Krueger, Nicholas D Landis, David A Eberhard, G David Young

Lab Invest· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diverse somatic mutation patterns and pathway alterations in human cancers.
Zhengyan Kan, Bijay S Jaiswal, Jeremy Stinson, Vasantharajan Janakiraman, Deepali Bhatt, David A Eberhard

Nature· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A tumor sorting protocol that enables enrichment of pancreatic adenocarcinoma cells and facilitation of genetic analyses.
Zachary S Boyd, Rajiv Raja, Stephanie Johnson, David A Eberhard, Mark R Lackner

J Mol Diagn· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.
David A Eberhard, Giuseppe Giaccone, Bruce E Johnson,

J Clin Oncol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
Roy S Herbst, Angela M Davies, Ronald B Natale, Thao P Dang, Joan H Schiller, David A Eberhard

Clin Cancer Res· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly efficient somatic-mutation identification using Escherichia coli mismatch-repair detection.
Brock A Peters, Zhengyan Kan, Dragan Sebisanovic, Kanan Pujara, Zhiyong Wang, David A Eberhard

Nat Methods· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
Michael S Gordon, Daniela Matei, Carol Aghajanian, Ursula A Matulonis, Molly Brewer, David A Eberhard

J Clin Oncol· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
Robert L Yauch, Thomas Januario, David A Eberhard, Guy Cavet, Wenjing Zhu

Clin Cancer Res· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
David A Eberhard, Bruce E Johnson, Lukas C Amler, Audrey D Goddard, Sherry L Heldens

J Clin Oncol· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib.
Daphne A Haas-Kogan, Michael D Prados, Tarik Tihan, David A Eberhard, Nannette Jelluma

J Natl Cancer Inst· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis